- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03847441
Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata
March 29, 2019 updated by: Moustafa A. El Taieb, Aswan University Hospital
Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata: A Randomized Controlled Trial
Alopecia Areata is a common condition.
This study investigated the efficacy of calcipotriol versus Narrow Band Ultraviolet B in treatment of Alopecia areata and their effects on serum vitamin D3 levels.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aswan, Egypt, 81528
- Aswan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 38 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Alopecia Areata of scalp
Exclusion Criteria:
Other causes of alopecias including scarring alopecia, androgenic alopecia, telogen effluvium autoimmune diseases, pregnant and lactating females
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group II
|
vitamin D3 (ng/ml)
NB-UVB (311nm) phototherapy
|
Active Comparator: Group III
|
Calcipotriol ointment (0.005%)
vitamin D3 (ng/ml)
NB-UVB (311nm) phototherapy
|
Active Comparator: Group I
|
Calcipotriol ointment (0.005%)
vitamin D3 (ng/ml)
|
Placebo Comparator: Group IV
|
vitamin D3 (ng/ml)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical improvement of Alopecia Areata After treatment As assessed by Severity of Alopecia tool (SALT) score
Time Frame: 3 months
|
calculation of SALT score before and after treatment
|
3 months
|
Improvement of serum Vitamin D levels in (ng/ml) after treatment
Time Frame: 3 months
|
measurement of serum vitamin D before and after treatment
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2017
Primary Completion (Actual)
December 31, 2018
Study Completion (Actual)
December 31, 2018
Study Registration Dates
First Submitted
February 18, 2019
First Submitted That Met QC Criteria
February 18, 2019
First Posted (Actual)
February 20, 2019
Study Record Updates
Last Update Posted (Actual)
April 2, 2019
Last Update Submitted That Met QC Criteria
March 29, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Alopecia Calcipotiol
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia Areata
-
Services Institute of Medical Sciences, PakistanCompletedExtensive Alopecia AreataPakistan
-
Eli Lilly and CompanyRecruitingSkin Diseases | Pathological Conditions, Anatomical | Alopecia | Hypotrichosis | Hair Diseases | Areata AlopeciaUnited States, Taiwan, Japan, Spain, Korea, Republic of, Germany, France, Mexico, Canada, Poland, Australia, Hungary, Argentina
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingAlopecia Areata(AA)China
-
University Hospital, RouenCompletedALOPECIA AREATAFrance
-
Inmagene LLCRecruitingAlopecia Areata (AA)United States, Canada
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Aclaris Therapeutics, Inc.CompletedAlopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Throne Biotechnologies Inc.RecruitingAlopecia Areata | Alopecia Totalis | Alopecia UniversalisUnited States
-
Jinnah HospitalCompletedAlopecia Areata | Alopecia Totalis | Alopecia UniversalisPakistan
Clinical Trials on Calcipotriol
-
Rabin Medical CenterUnknown
-
LEO PharmaCompletedPsoriasis VulgarisBelgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
-
DaniscoUniversity of Turku; 4Pharma Ltd.CompletedBorderline HypertensionFinland
-
LEO PharmaCompletedAtopic DermatitisUnited Kingdom, Finland, Canada, Denmark
-
Circassia LimitedBioskin GmbHCompletedPsoriasis VulgarisGermany
-
Wake Forest University Health SciencesWithdrawnCentral Centrifugal Cicatricial AlopeciaUnited States
-
Guangdong Provincial Hospital of Traditional Chinese...CompletedPsoriasis | Drug Effect | Drug Toxicity | Mesenchymal Stromal CellsChina
-
Xijing HospitalCompleted
-
LEO PharmaCompletedPsoriasis VulgarisFrance